A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients

Trial Profile

A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs PX 104 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions
  • Sponsors Phenex Pharmaceuticals
  • Most Recent Events

    • 29 Sep 2016 Biomarkers information updated
    • 02 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top